Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#1351 Sunitinib (SU) in Patients with Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): Final Overall Survival (OS) Results from a Phase III Randomized Study Including Adjustment for Crossover

Introduction: This pivotal, Phase 3, double-blind study of SU in patients (pts) with advanced, progressive pNETs met its primary endpoint with median progression-free survival of 11.4 months (mo) for SU vs 5.5 mo for placebo (PBO; HR=0.42; 95% CI 0.26–0.66; p<0.001). OS difference favored SU (HR=0.41; 95% CI 0.19–0.89; p=0.02). At 2 years after study closure, median OS was 33.0 mo for SU vs 26.7 mo for PBO (HR=0.71; 95% CI 0.47–1.09; p=0.115).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Raymond E

Authors: Raymond E, Niccoli P, Castellano D, Valle J, Hammel P,

Keywords: sutent, OS,

#325 Effect of Everolimus + Octreotide LAR Treatment on 5-Hydroxyindoleacetic Acid Levels in Patients With Advanced Neuroendocrine Tumors: Phase III RADIANT-2 Study Results

Introduction: Urinary 5-hydroxyindoleacetic acid (5-HIAA) is a metabolite and surrogate measure of plasma serotonin, an important cause of carcinoid syndrome in patients with neuroendocrine tumors (NET).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Baudin E, Wolin E, Castellano D, Kaltsas G, Lebrec J,

Keywords: mTOR, everolimus, octreotide, 5-hydroxyindoleacetic acid, 5-HIAA,

#280 Sorafenib and Bevacizumab Combination Targeted Therapy in Advanced Neuroendocrine Tumor: A Phase II Study of the Spanish Neuroendocrine Tumor Group (GETNE0801)

Introduction: Sorafenib (S) and bevacizumab (B) as single agents have shown efficacy and acceptable toxicity in NETs phase II trials. S+B combination has shown manageable toxicity in phase I trials in solid tumors.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Castellano D, Capdevila J, Salazar R, Sastre J, Alonso V,

Keywords: targeted therapy, sorafenib, bevacizumab,

#232 Prognostic Factors and Survival in 481 Patients with Pancreatic and Peripancreatic Endocrine Tumors: Results from the National Cancer Registry of Spain (RGETNE)

Introduction: Duodenopancreatic neuroendocrine tumors (NETs) are uncommon neoplasms with a wide spectrum of clinical presentation. The infrequent occurrence of these tumors makes large experiences very scarce.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Martin-Perez E, Capdevila J, Castellano D, Jiménez-Lacave A, Beguiristain-Gómez A,

Keywords: pancreatic neuroendocrine tumors, gastrinoma, glucagonoma, insulinoma, registry, survival, treatment,